Gilead Sciences (GILD) Financials

$111.11 +2.67 (+2.46%)

Closing price 04:00 PM Eastern

Extended Trading

$111.04 -0.08 (-0.07%)

As of 07:58 PM Eastern

Annual Income Statements for Gilead Sciences

This table shows Gilead Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	480	5,665	4,592	6,225	123	5,386	5,455	4,628	13,501	18,108
Consolidated Net Income / (Loss)	480	5,613	4,566	6,201	89	5,364	5,460	4,644	13,488	18,106
Net Income / (Loss) Continuing Operations	479	5,612	4,566	6,201	89	5,364	5,460	4,644	13,488	18,106
Total Pre-Tax Income	690	6,859	5,814	8,278	1,669	5,160	7,799	13,529	17,097	21,659
Total Operating Income	1,662	7,605	7,330	9,918	4,071	4,287	8,200	14,124	17,633	22,193
Total Gross Profit	22,503	20,618	21,624	20,704	20,117	17,774	17,274	21,736	26,129	28,633
Total Revenue	28,754	27,116	27,281	27,305	24,689	22,449	22,127	26,107	30,390	32,639
Operating Revenue	28,754	27,116	27,281	27,305	24,689	22,449	22,127	26,107	30,390	32,151
Total Cost of Revenue	6,251	6,498	5,657	6,601	4,572	4,675	4,853	4,371	4,261	4,006
Operating Cost of Revenue	6,251	6,498	5,657	6,601	4,572	4,675	4,853	4,371	4,261	4,006
Total Operating Expenses	20,841	13,013	14,294	10,786	16,046	13,487	9,074	7,612	8,496	6,440
Selling, General & Admin Expense	6,091	6,090	5,673	5,246	5,151	4,381	4,056	3,878	3,398	3,426
Research & Development Expense	10,570	6,873	5,921	5,540	10,895	9,106	5,018	3,734	5,098	3,014
Impairment Charge	4,180	50	2,700	0.00	0.00	-	-	-	-	-
Total Other Income / (Expense), net	-971	-746	-1,516	-1,640	-2,402	873	-401	-595	-536	-534
Interest Expense	977	944	935	1,001	984	995	1,077	1,118	964	688
Other Income / (Expense), net	6.00	198	-581	-639	-1,418	1,868	676	523	428	154
Income Tax Expense	211	1,247	1,248	2,077	1,580	-204	2,339	8,885	3,609	3,553
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	-52	-26	-24	-34	-22	5.00	16	-13	-2.00
Basic Earnings per Share	$0.38	$4.54	$3.66	$4.96	$0.10	$4.24	$4.20	$3.54	$10.08	$12.37
Weighted Average Basic Shares Outstanding	1.25B	1.25B	1.26B	1.26B	1.26B	1.27B	1.30B	1.31B	1.34B	1.46B
Diluted Earnings per Share	$0.38	$4.50	$3.64	$4.93	$0.10	$4.22	$4.17	$3.51	$9.94	$11.91
Weighted Average Diluted Shares Outstanding	1.26B	1.26B	1.26B	1.26B	1.26B	1.28B	1.31B	1.32B	1.36B	1.52B
Weighted Average Basic & Diluted Shares Outstanding	1.25B	1.25B	1.25B	1.25B	1.26B	1.26B	1.30B	1.31B	1.34B	1.46B
Cash Dividends to Common per Share	$3.08	$3.00	$2.92	$2.84	$2.72	$2.52	$2.28	$2.08	$1.84	$1.29

This table shows Gilead Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	1,315	1,783	1,253	1,614	-4,170	1,430	2,180	1,045	1,010	1,640	1,789
Consolidated Net Income / (Loss)	1,315	1,783	1,253	1,614	-4,170	1,417	2,172	1,039	985	1,633	1,786
Net Income / (Loss) Continuing Operations	1,315	1,782	1,253	1,615	-4,171	1,417	2,172	1,039	984	1,633	1,786
Total Pre-Tax Income	1,649	2,167	956	2,053	-4,486	1,653	2,318	1,588	1,300	2,031	2,432
Total Operating Income	2,237	2,452	888	2,644	-4,322	1,612	2,623	1,665	1,705	2,267	2,837
Total Gross Profit	5,127	5,988	5,971	5,410	5,134	5,024	5,486	5,157	4,951	5,993	5,647
Total Revenue	6,667	7,569	7,545	6,954	6,686	7,114	7,051	6,599	6,352	7,389	7,042
Operating Revenue	6,667	7,569	7,545	6,954	6,686	7,114	7,051	6,599	6,352	7,389	7,042
Total Cost of Revenue	1,540	1,581	1,574	1,544	1,552	2,090	1,565	1,442	1,401	1,396	1,395
Operating Cost of Revenue	1,540	1,581	1,574	1,544	1,552	2,090	1,565	1,442	1,401	1,396	1,395
Total Operating Expenses	2,890	3,536	5,083	2,766	9,456	3,411	2,863	3,492	3,247	3,726	2,810
Selling, General & Admin Expense	1,258	1,906	1,433	1,377	1,375	1,607	1,315	1,849	1,319	2,020	1,213
Research & Development Expense	1,632	1,630	1,900	1,389	5,651	1,754	1,548	1,643	1,928	1,706	1,597
Impairment Charge	0.00	-	1,750	0.00	2,430	50	0.00	0.00	0.00	-	0.00
Total Other Income / (Expense), net	-588	-284	68	-592	-163	40	-304	-78	-404	-236	-405
Interest Expense	260	248	238	237	254	252	232	230	230	226	229
Other Income / (Expense), net	-328	-36	306	-355	91	292	-72	152	-174	-10	-176
Income Tax Expense	334	385	-297	438	-315	236	146	549	316	398	646
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	-	0.00	0.00	0.00	-12	-8.00	-6.00	-26	-7.00	-3.00
Basic Earnings per Share	$1.06	$1.43	$1.00	$1.29	($3.34)	$1.14	$1.75	$0.84	$0.81	$1.30	$1.43
Weighted Average Basic Shares Outstanding	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.26B	1.26B
Diluted Earnings per Share	$1.04	$1.43	$1.00	$1.29	($3.34)	$1.14	$1.73	$0.83	$0.80	$1.29	$1.42
Weighted Average Diluted Shares Outstanding	1.26B	1.26B	1.25B	1.25B	1.25B	1.26B	1.26B	1.26B	1.26B	1.26B	1.26B
Weighted Average Basic & Diluted Shares Outstanding	1.24B	1.25B	1.25B	1.24B	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B
Cash Dividends to Common per Share	$0.79	-	$0.77	$0.77	$0.77	-	$0.75	$0.75	$0.75	-	$0.73

This table details how cash moves in and out of Gilead Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	3,906	673	74	-659	-5,634	-6,309	10,437	-778	-4,622	2,824
Net Cash From Operating Activities	10,828	8,006	9,072	11,384	8,168	9,144	8,400	11,898	17,047	21,250
Net Cash From Continuing Operating Activities	10,828	8,005	9,072	11,384	8,168	9,144	8,400	11,898	17,047	21,250
Net Income / (Loss) Continuing Operations	480	5,613	4,566	6,201	89	5,364	5,460	4,644	13,488	18,106
Consolidated Net Income / (Loss)	480	5,613	4,566	6,201	89	5,364	5,460	4,644	13,488	18,106
Depreciation Expense	381	354	323	329	288	255	226	233	177	161
Amortization Expense	2,386	2,339	1,780	1,721	1,192	1,149	1,203	1,053	981	937
Non-Cash Adjustments To Reconcile Net Income	10,305	2,964	5,718	2,760	8,451	5,272	2,161	942	974	944
Changes in Operating Assets and Liabilities, net	-2,724	-3,265	-3,315	373	-1,852	-2,896	-650	5,026	1,427	1,102
Net Cash From Investing Activities	-3,449	-2,265	-2,466	-3,131	-14,615	-7,817	14,355	-16,069	-11,985	-12,475
Net Cash From Continuing Investing Activities	-3,449	-2,266	-2,466	-3,131	-14,615	-7,817	14,355	-16,069	-11,985	-12,475
Purchase of Property, Plant & Equipment	-523	-585	-728	-579	-650	-825	-924	-590	-748	-747
Acquisitions	-4,840	-1,152	-1,797	-1,584	-25,920	-4,251	0.00	-10,426	0.00	0.00
Purchase of Investments	-736	-2,372	-1,942	-3,897	-20,770	-32,228	-10,389	-23,314	-25,976	-17,239
Sale and/or Maturity of Investments	2,592	1,844	2,002	2,910	32,718	29,921	25,858	18,261	14,739	5,511
Other Investing Activities, net	58	-1.00	-1.00	19	7.00	-434	-190	0.00	-	-
Net Cash From Financing Activities	-3,433	-5,125	-6,469	-8,877	770	-7,634	-12,318	3,393	-9,725	-5,884
Net Cash From Continuing Financing Activities	-3,433	-5,126	-6,469	-8,877	770	-7,634	-12,318	3,393	-9,725	-5,884
Repayment of Debt	-2,251	-2,529	-1,673	-4,895	-2,638	-2,872	-6,736	-2,141	-2,257	-5,013
Repurchase of Common Equity	-1,150	-1,000	-1,396	-546	-1,583	-1,749	-2,900	-954	-11,001	-10,002
Payment of Dividends	-3,918	-3,809	-3,709	-3,605	-3,449	-3,222	-2,971	-2,731	-2,455	-1,874
Issuance of Debt	3,464	1,980	0.00	0.00	8,184	-	0.00	8,985	5,293	9,902
Issuance of Common Equity	422	232	309	169	256	209	289	234	208	319
Effect of Exchange Rate Changes	-40	57	-63	-35	43	-2.00	-	-	41	-67
Cash Interest Paid	951	891	907	979	951	982	1,070	1,038	885	529
Cash Income Taxes Paid	2,779	3,990	3,136	2,509	2,639	1,793	3,198	3,342	2,436	3,137

This table details how cash moves in and out of Gilead Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-2,065	4,955	2,264	-1,946	-1,367	380	1.00	768	-476	713	-40
Net Cash From Operating Activities	1,757	2,975	4,309	1,325	2,219	2,169	1,755	2,338	1,744	2,567	2,863
Net Cash From Continuing Operating Activities	1,758	2,976	4,309	1,324	2,219	2,167	1,756	2,337	1,745	2,567	2,863
Net Income / (Loss) Continuing Operations	1,315	1,783	1,253	1,614	-4,170	1,417	2,172	1,039	985	1,633	1,786
Consolidated Net Income / (Loss)	1,315	1,783	1,253	1,614	-4,170	1,417	2,172	1,039	985	1,633	1,786
Depreciation Expense	97	95	94	98	94	91	86	83	94	83	80
Amortization Expense	599	598	596	596	596	597	598	598	546	445	445
Non-Cash Adjustments To Reconcile Net Income	979	396	2,300	728	6,881	975	517	507	965	627	939
Changes in Operating Assets and Liabilities, net	-1,232	104	66	-1,712	-1,182	-913	-1,617	110	-845	-221	-387
Net Cash From Investing Activities	-415	-225	-710	-307	-2,207	-727	-229	-483	-826	-375	-713
Net Cash From Continuing Investing Activities	-416	-226	-709	-309	-2,205	-728	-229	-483	-826	-375	-713
Purchase of Property, Plant & Equipment	-104	-147	-141	-130	-105	-215	-122	-139	-109	-181	-157
Acquisitions	-273	-75	-570	-152	-4,043	-279	-79	-243	-551	-218	-448
Purchase of Investments	-16	-39	-9.00	-34	-654	-680	-395	-645	-652	-378	-430
Sale and/or Maturity of Investments	0.00	-	-	-	2,592	447	361	545	491	400	324
Other Investing Activities, net	-23	35	11	7.00	5.00	-1.00	6.00	-1.00	-5.00	2.00	-2.00
Net Cash From Financing Activities	-3,426	2,260	-1,379	-2,953	-1,361	-1,099	-1,519	-1,101	-1,406	-1,554	-2,118
Net Cash From Continuing Financing Activities	-3,426	2,260	-1,379	-2,954	-1,360	-1,100	-1,519	-1,100	-1,407	-1,554	-2,118
Repayment of Debt	-1,938	-54	-194	-1,887	-116	-34	-2,328	-32	-135	-23	-1,045
Repurchase of Common Equity	-730	-350	-300	-100	-400	-150	-300	-150	-400	-792	-180
Payment of Dividends	-1,010	-973	-983	-972	-990	-943	-953	-944	-969	-915	-929
Issuance of Common Equity	252	173	98	5.00	146	26	83	26	97	176	36
Effect of Exchange Rate Changes	19	-55	44	-11	-18	37	-6.00	13	13	75	-72

This table presents Gilead Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	58,995	62,125	63,171	67,952	68,407	61,627	63,675	70,283	56,977	51,716
Total Current Assets	19,173	16,085	14,443	14,772	15,996	30,296	35,836	31,823	19,588	24,762
Cash & Equivalents	9,991	6,085	5,412	5,338	5,997	11,631	17,940	7,588	8,229	12,851
Short-Term Investments	0.00	1,179	973	1,182	1,411	12,721	12,149	17,922	3,666	1,756
Accounts Receivable	4,420	4,660	4,777	4,493	4,892	3,582	3,327	3,851	4,514	5,854
Inventories, net	1,710	1,787	1,507	1,618	1,683	922	814	801	1,587	1,955
Prepaid Expenses	3,052	2,374	1,774	2,141	2,013	1,440	1,606	1,661	1,592	1,518
Plant, Property, & Equipment, net	5,414	5,317	5,475	5,121	4,967	4,502	4,006	3,295	2,865	2,276
Total Noncurrent Assets	34,408	40,723	43,253	48,059	47,444	26,829	23,833	35,165	34,524	24,678
Long-Term Investments	0.00	1,163	1,245	1,309	502	1,488	1,423	11,184	20,485	11,601
Goodwill	8,314	8,314	8,314	8,332	8,108	4,117	4,117	4,159	1,172	1,172
Intangible Assets	19,948	26,454	28,894	33,455	33,126	13,786	15,738	17,100	8,971	10,247
Other Noncurrent Operating Assets	6,146	4,792	4,800	4,963	5,708	7,438	2,555	2,722	3,896	1,334
Total Liabilities & Shareholders' Equity	58,995	62,125	63,171	67,952	68,407	61,627	63,675	70,283	56,977	51,716
Total Liabilities	39,749	39,376	41,962	46,888	50,186	38,977	42,141	49,782	37,614	32,601
Total Current Liabilities	12,004	11,280	11,237	11,610	11,397	9,759	10,605	11,635	9,218	9,890
Short-Term Debt	1,815	1,798	2,273	1,516	2,757	2,499	2,748	2,747	0.00	982
Accounts Payable	833	550	905	705	5,180	713	790	814	1,206	1,178
Accrued Expenses	3,892	3,802	3,479	3,244	3,460	6,547	7,067	8,074	8,012	7,290
Other Current Liabilities	5,464	5,130	4,580	6,145	-	-	-	-	-	-
Total Noncurrent Liabilities	27,745	28,096	30,725	35,278	38,789	29,218	31,536	38,147	28,396	22,711
Long-Term Debt	24,896	23,189	22,957	25,179	28,645	22,094	24,574	30,795	26,346	21,073
Noncurrent Deferred Revenue	830	2,039	3,916	4,767	5,016	6,115	5,922	6,794	1,753	1,243
Noncurrent Deferred & Payable Income Tax Liabilities	724	1,588	2,673	4,356	3,914	-	-	-	-	-
Other Noncurrent Operating Liabilities	1,295	1,280	1,179	976	1,214	1,009	1,040	558	297	395
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	19,246	22,749	21,209	21,064	18,221	22,650	21,534	20,501	19,363	19,113
Total Preferred & Common Equity	19,330	22,833	21,240	21,069	18,202	22,525	21,387	20,442	18,887	18,534
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	19,330	22,833	21,240	21,069	18,202	22,525	21,387	20,442	18,887	18,534
Common Stock	7,701	6,501	5,551	4,662	3,881	3,052	2,283	1,265	455	445
Retained Earnings	11,497	16,304	15,687	16,324	14,381	19,388	19,024	19,012	18,154	18,001
Accumulated Other Comprehensive Income / (Loss)	132	28	2.00	83	-60	85	80	165	278	88
Noncontrolling Interest	-84	-84	-31	-5.00	19	125	147	59	476	579

This table presents Gilead Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Total Assets	56,434	58,995	54,525	53,579	56,292	62,125	62,373	62,337	61,876	63,171	62,557
Total Current Assets	16,901	19,173	14,779	12,317	14,041	16,085	15,980	14,287	13,456	14,443	13,554
Cash & Equivalents	7,926	9,991	5,037	2,772	4,718	6,085	5,705	5,704	4,936	5,412	4,699
Accounts Receivable	4,388	4,420	4,587	4,663	4,669	4,660	4,790	4,229	4,162	4,777	4,354
Inventories, net	1,759	1,710	1,869	2,026	1,853	1,787	1,663	1,633	1,576	1,507	1,463
Prepaid Expenses	2,828	3,052	3,287	2,856	2,800	2,374	2,662	1,757	1,846	1,774	2,077
Plant, Property, & Equipment, net	5,421	5,414	5,391	5,346	5,321	5,317	5,572	5,540	5,479	5,475	5,349
Total Noncurrent Assets	34,112	34,408	34,354	35,916	36,930	40,723	40,822	42,511	42,941	43,253	43,654
Goodwill	8,314	8,314	8,314	8,314	8,314	8,314	8,314	8,314	8,314	8,314	8,314
Intangible Assets	19,355	19,948	20,546	22,832	23,428	26,454	27,152	27,750	28,348	28,894	29,440
Noncurrent Deferred & Refundable Income Taxes	2,572	-	-	-	-	-	-	-	-	-	-
Other Noncurrent Operating Assets	3,871	6,146	5,494	4,770	5,188	4,792	4,200	5,113	4,952	4,800	4,618
Total Liabilities & Shareholders' Equity	56,434	58,995	54,525	53,579	56,292	62,125	62,373	62,337	61,876	63,171	62,557
Total Liabilities	37,355	39,749	36,134	35,384	38,837	39,376	40,130	41,243	40,937	41,962	41,500
Total Current Liabilities	12,344	12,004	11,725	10,781	13,015	11,280	11,945	13,964	10,528	11,237	10,423
Short-Term Debt	2,806	1,815	1,812	1,810	3,667	1,798	1,793	4,037	2,283	2,273	2,270
Accounts Payable	737	833	903	537	622	550	586	622	627	905	614
Accrued Expenses	4,185	3,892	4,113	3,923	4,263	3,802	3,714	3,494	3,477	3,479	7,539
Other Current Liabilities	4,615	5,464	4,896	4,510	4,464	5,130	5,852	5,810	4,140	4,580	-
Total Noncurrent Liabilities	25,011	27,745	24,409	24,603	25,822	28,096	28,185	27,279	30,409	30,725	31,077
Long-Term Debt	22,146	24,896	21,437	21,540	21,527	23,189	23,189	21,209	22,956	22,957	22,953
Noncurrent Deferred Revenue	819	830	782	738	1,967	2,039	2,088	2,610	3,775	3,916	3,982
Noncurrent Deferred & Payable Income Tax Liabilities	709	724	794	907	933	1,588	1,984	2,106	2,401	2,673	3,036
Other Noncurrent Operating Liabilities	1,337	1,295	1,396	1,418	1,395	1,280	924	1,354	1,277	1,179	1,106
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	19,078	19,246	18,390	18,197	17,455	22,749	22,242	21,094	20,939	21,209	21,057
Total Preferred & Common Equity	19,162	19,330	18,475	18,281	17,539	22,833	22,314	21,158	20,997	21,240	21,081
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	19,162	19,330	18,474	18,281	17,539	22,833	22,313	21,157	20,997	21,240	21,081
Common Stock	8,139	7,701	7,328	7,023	6,814	6,501	6,280	6,009	5,794	5,551	5,227
Retained Earnings	10,931	11,497	11,073	11,165	10,656	16,304	16,002	15,138	15,223	15,687	15,756
Accumulated Other Comprehensive Income / (Loss)	92	132	73	93	69	28	31	10	-20	2.00	98
Noncontrolling Interest	-84	-84	-84	-84	-84	-84	-72	-64	-58	-31	-24

This table displays calculated financial ratios and metrics derived from Gilead Sciences' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	6.04%	-0.60%	-0.09%	10.60%	9.98%	1.46%	-15.25%	-14.09%	-6.89%	31.13%
EBITDA Growth	-57.75%	18.57%	-21.86%	174.11%	-45.32%	-26.65%	-35.32%	-17.10%	-18.03%	43.68%
EBIT Growth	-78.62%	15.62%	-27.27%	249.76%	-56.90%	-30.66%	-39.40%	-18.90%	-19.18%	46.36%
NOPAT Growth	-81.46%	8.09%	-22.52%	3,322.36%	-95.13%	-22.37%	18.41%	-65.15%	-25.02%	49.72%
Net Income Growth	-91.45%	22.93%	-26.37%	6,867.42%	-98.34%	-1.76%	17.57%	-65.57%	-25.51%	50.15%
EPS Growth	-91.56%	23.63%	-26.17%	4,830.00%	-97.63%	1.20%	18.80%	-64.69%	-16.54%	62.04%
Operating Cash Flow Growth	35.25%	-11.75%	-20.31%	39.37%	-10.67%	8.86%	-29.40%	-30.20%	-19.78%	65.78%
Free Cash Flow Firm Growth	-21.42%	-16.80%	-25.35%	145.85%	-5,155.00%	-93.08%	593.73%	-94.67%	-22.68%	71.04%
Invested Capital Growth	-8.50%	1.29%	-2.81%	-4.27%	94.89%	23.40%	-0.03%	30.16%	-10.91%	-9.39%
Revenue Q/Q Growth	1.61%	-1.00%	0.53%	-0.64%	6.66%	0.38%	-0.69%	-4.99%	-3.76%	3.79%
EBITDA Q/Q Growth	13.20%	-1.81%	16.49%	-7.93%	0.34%	12.89%	-10.34%	-9.42%	-7.10%	5.92%
EBIT Q/Q Growth	44.29%	-4.33%	22.96%	-10.46%	-2.32%	16.48%	-11.47%	-10.74%	-7.58%	6.21%
NOPAT Q/Q Growth	116.70%	-6.46%	31.63%	-19.08%	-87.71%	63.99%	237.55%	-59.59%	-10.57%	7.52%
Net Income Q/Q Growth	321.05%	-3.71%	37.99%	-15.85%	-92.79%	100.30%	236.83%	-59.89%	-10.52%	7.24%
EPS Q/Q Growth	322.22%	-3.23%	37.36%	-16.16%	-89.80%	100.95%	239.02%	-60.02%	-7.71%	3.03%
Operating Cash Flow Q/Q Growth	8.04%	-4.74%	-6.57%	12.77%	-7.52%	2.64%	-4.63%	-6.20%	-11.69%	15.01%
Free Cash Flow Firm Q/Q Growth	43.51%	-15.66%	-6.50%	174.14%	-1,614.20%	-79.35%	224.28%	-92.90%	-12.65%	12.90%
Invested Capital Q/Q Growth	-1.74%	0.27%	-1.34%	-5.65%	101.40%	5.57%	-10.97%	31.87%	3.97%	-0.64%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	78.26%	76.04%	79.26%	75.82%	81.48%	79.18%	78.07%	83.26%	85.98%	87.73%
EBITDA Margin	15.42%	38.71%	32.45%	41.49%	16.74%	33.67%	46.57%	61.03%	63.24%	71.83%
Operating Margin	5.78%	28.05%	26.87%	36.32%	16.49%	19.10%	37.06%	54.10%	58.02%	68.00%
EBIT Margin	5.80%	28.78%	24.74%	33.98%	10.75%	27.42%	40.11%	56.10%	59.43%	68.47%
Profit (Net Income) Margin	1.67%	20.70%	16.74%	22.71%	0.36%	23.89%	24.68%	17.79%	44.38%	55.47%
Tax Burden Percent	69.57%	81.83%	78.53%	74.91%	5.33%	103.95%	70.01%	34.33%	78.89%	83.60%
Interest Burden Percent	41.37%	87.90%	86.15%	89.21%	62.91%	83.83%	87.87%	92.37%	94.66%	96.92%
Effective Tax Rate	30.58%	18.18%	21.47%	25.09%	94.67%	-3.95%	29.99%	65.67%	21.11%	16.40%
Return on Invested Capital (ROIC)	3.07%	15.93%	14.62%	18.20%	0.69%	23.00%	33.09%	31.61%	98.34%	117.89%
ROIC Less NNEP Spread (ROIC-NNEP)	-0.98%	12.36%	8.09%	12.40%	-0.46%	-10.38%	40.74%	36.05%	106.64%	143.58%
Return on Net Nonoperating Assets (RNNOA)	-0.78%	9.61%	6.98%	13.37%	-0.25%	1.28%	-7.12%	-8.31%	-28.23%	-14.28%
Return on Equity (ROE)	2.29%	25.54%	21.60%	31.57%	0.44%	24.28%	25.98%	23.30%	70.11%	103.61%
Cash Return on Invested Capital (CROIC)	11.95%	14.65%	17.47%	22.57%	-63.67%	2.05%	33.12%	5.40%	109.89%	127.74%
Operating Return on Assets (OROA)	2.75%	12.46%	10.29%	13.61%	4.08%	9.82%	13.25%	23.02%	33.23%	51.74%
Return on Assets (ROA)	0.79%	8.96%	6.96%	9.10%	0.14%	8.56%	8.15%	7.30%	24.82%	41.92%
Return on Common Equity (ROCE)	2.30%	25.60%	21.62%	31.56%	0.43%	24.13%	25.85%	22.99%	68.18%	100.68%
Return on Equity Simple (ROE_SIMPLE)	2.48%	24.58%	21.50%	29.43%	0.49%	23.81%	25.53%	22.72%	71.41%	97.69%
Net Operating Profit after Tax (NOPAT)	1,154	6,222	5,757	7,430	217	4,456	5,741	4,848	13,911	18,552
NOPAT Margin	4.01%	22.95%	21.10%	27.21%	0.88%	19.85%	25.94%	18.57%	45.77%	56.84%
Net Nonoperating Expense Percent (NNEP)	4.05%	3.57%	6.53%	5.80%	1.15%	33.38%	-7.65%	-4.45%	-8.30%	-25.69%
Return On Investment Capital (ROIC_SIMPLE)	2.51%	13.04%	12.40%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	21.74%	23.96%	20.74%	24.18%	18.52%	20.83%	21.93%	16.74%	14.02%	12.27%
SG&A Expenses to Revenue	21.18%	22.46%	20.79%	19.21%	20.86%	19.52%	18.33%	14.85%	11.18%	10.50%
R&D to Revenue	36.76%	25.35%	21.70%	20.29%	44.13%	40.56%	22.68%	14.30%	16.78%	9.23%
Operating Expenses to Revenue	72.48%	47.99%	52.40%	39.50%	64.99%	60.08%	41.01%	29.16%	27.96%	19.73%
Earnings before Interest and Taxes (EBIT)	1,668	7,803	6,749	9,279	2,653	6,155	8,876	14,647	18,061	22,347
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	4,435	10,496	8,852	11,329	4,133	7,559	10,305	15,933	19,219	23,445
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.96	4.25	4.69	3.89	3.46	3.03	3.02	3.55	3.76	5.79
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	14.76	42.21	0.00	8.12	15.08
Price to Revenue (P/Rev)	4.00	3.58	3.65	3.00	2.55	3.04	2.92	2.78	2.34	3.29
Price to Earnings (P/E)	239.83	17.12	21.69	13.17	512.71	12.67	11.85	15.66	5.26	5.92
Dividend Yield	3.33%	3.85%	3.68%	4.34%	5.41%	4.67%	4.56%	3.75%	3.41%	1.73%
Earnings Yield	0.42%	5.84%	4.61%	7.59%	0.20%	7.90%	8.44%	6.39%	19.01%	16.88%
Enterprise Value to Invested Capital (EV/IC)	3.66	2.89	3.02	2.53	2.08	3.13	3.49	4.00	4.91	6.93
Enterprise Value to Revenue (EV/Rev)	4.58	4.18	4.30	3.69	3.51	2.99	2.74	2.66	2.15	3.18
Enterprise Value to EBITDA (EV/EBITDA)	29.71	10.81	13.24	8.90	20.95	8.88	5.88	4.36	3.41	4.42
Enterprise Value to EBIT (EV/EBIT)	78.99	14.54	17.36	10.87	32.63	10.90	6.83	4.74	3.62	4.64
Enterprise Value to NOPAT (EV/NOPAT)	114.19	18.23	20.35	13.58	398.80	15.06	10.56	14.31	4.70	5.59
Enterprise Value to Operating Cash Flow (EV/OCF)	12.17	14.17	12.92	8.86	10.60	7.34	7.22	5.83	3.84	4.88
Enterprise Value to Free Cash Flow (EV/FCFF)	29.30	19.83	17.04	10.95	0.00	168.80	10.55	83.78	4.21	5.16
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.39	1.10	1.19	1.27	1.72	1.09	1.27	1.64	1.36	1.15
Long-Term Debt to Equity	1.29	1.02	1.08	1.20	1.57	0.98	1.14	1.50	1.36	1.10
Financial Leverage	0.79	0.78	0.86	1.08	0.54	-0.12	-0.17	-0.23	-0.26	-0.10
Leverage Ratio	2.88	2.85	3.10	3.47	3.18	2.84	3.19	3.19	2.82	2.47
Compound Leverage Factor	1.19	2.51	2.67	3.10	2.00	2.38	2.80	2.95	2.67	2.40
Debt to Total Capital	58.12%	52.34%	54.33%	55.90%	63.28%	52.06%	55.92%	62.07%	57.64%	53.57%
Short-Term Debt to Total Capital	3.95%	3.77%	4.89%	3.17%	5.56%	5.29%	5.62%	5.08%	0.00%	2.39%
Long-Term Debt to Total Capital	54.17%	48.58%	49.43%	52.72%	57.73%	46.77%	50.30%	56.98%	57.64%	51.19%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-0.18%	-0.18%	-0.07%	-0.01%	0.04%	0.26%	0.30%	0.11%	1.04%	1.41%
Common Equity to Total Capital	42.06%	47.83%	45.74%	44.12%	36.68%	47.68%	43.78%	37.83%	41.32%	45.02%
Debt to EBITDA	6.02	2.38	2.85	2.36	7.60	3.25	2.65	2.11	1.37	0.94
Net Debt to EBITDA	3.77	1.58	1.99	1.67	5.68	-0.17	-0.41	-0.20	-0.31	-0.18
Long-Term Debt to EBITDA	5.61	2.21	2.59	2.22	6.93	2.92	2.38	1.93	1.37	0.90
Debt to NOPAT	23.15	4.02	4.38	3.59	144.65	5.52	4.76	6.92	1.89	1.19
Net Debt to NOPAT	14.49	2.66	3.06	2.54	108.21	-0.28	-0.73	-0.65	-0.43	-0.22
Long-Term Debt to NOPAT	21.58	3.73	3.99	3.39	131.95	4.96	4.28	6.35	1.89	1.14
Altman Z-Score	2.74	2.79	2.62	2.29	1.62	2.58	2.62	2.66	3.38	4.86
Noncontrolling Interest Sharing Ratio	-0.40%	-0.26%	-0.09%	0.04%	0.35%	0.62%	0.49%	1.34%	2.75%	2.83%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.60	1.43	1.29	1.27	1.40	3.10	3.38	2.74	2.13	2.50
Quick Ratio	1.20	1.06	0.99	0.95	1.08	2.86	3.15	2.52	1.78	2.07
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	4,497	5,722	6,878	9,213	-20,093	397	5,746	828	15,544	20,102
Operating Cash Flow to CapEx	2,070.36%	1,368.55%	1,246.15%	1,966.15%	1,256.62%	1,108.36%	909.09%	2,016.61%	2,279.01%	2,844.71%
Free Cash Flow to Firm to Interest Expense	4.60	6.06	7.36	9.20	-20.42	0.40	5.33	0.74	16.12	29.22
Operating Cash Flow to Interest Expense	11.08	8.48	9.70	11.37	8.30	9.19	7.80	10.64	17.68	30.89
Operating Cash Flow Less CapEx to Interest Expense	10.55	7.86	8.92	10.79	7.64	8.36	6.94	10.11	16.91	29.80
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.47	0.43	0.42	0.40	0.38	0.36	0.33	0.41	0.56	0.76
Accounts Receivable Turnover	6.33	5.75	5.89	5.82	5.83	6.50	6.17	6.24	5.86	6.22
Inventory Turnover	3.58	3.95	3.62	4.00	3.51	5.39	6.01	3.66	2.41	2.40
Fixed Asset Turnover	5.36	5.03	5.15	5.41	5.21	5.28	6.06	8.48	11.82	16.53
Accounts Payable Turnover	9.04	8.93	7.03	2.24	1.55	6.22	6.05	4.33	3.57	3.76
Days Sales Outstanding (DSO)	57.63	63.51	62.01	62.73	62.64	56.17	59.20	58.48	62.26	58.65
Days Inventory Outstanding (DIO)	102.10	92.51	100.82	91.26	103.98	67.77	60.73	99.70	151.71	152.20
Days Payable Outstanding (DPO)	40.38	40.86	51.94	162.70	235.23	58.67	60.32	84.34	102.11	97.17
Cash Conversion Cycle (CCC)	119.35	115.16	110.89	-8.71	-68.61	65.26	59.62	73.84	111.86	113.68
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	35,966	39,309	38,809	39,930	41,713	21,403	17,344	17,349	13,329	14,962
Invested Capital Turnover	0.76	0.69	0.69	0.67	0.78	1.16	1.28	1.70	2.15	2.07
Increase / (Decrease) in Invested Capital	-3,343	500	-1,121	-1,783	20,310	4,059	-5.00	4,020	-1,633	-1,550
Enterprise Value (EV)	131,754	113,455	117,171	100,871	86,575	67,097	60,616	69,388	65,444	103,699
Market Capitalization	115,118	96,979	99,602	82,010	63,064	68,219	64,659	72,481	71,002	107,271
Book Value per Share	$15.51	$18.32	$16.93	$16.80	$14.52	$17.80	$16.53	$15.65	$14.34	$12.86
Tangible Book Value per Share	($7.17)	($9.58)	($12.73)	($16.52)	($18.37)	$3.65	$1.18	($0.63)	$6.64	$4.94
Total Capital	45,957	47,736	46,439	47,759	49,623	47,243	48,856	54,043	45,709	41,170
Total Debt	26,711	24,987	25,230	26,695	31,402	24,593	27,322	33,542	26,346	22,055
Total Long-Term Debt	24,896	23,189	22,957	25,179	28,645	22,094	24,574	30,795	26,346	21,073
Net Debt	16,720	16,560	17,600	18,866	23,492	-1,247	-4,190	-3,152	-6,034	-4,153
Capital Expenditures (CapEx)	523	585	728	579	650	825	924	590	748	747
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1,007	-661	-906	-1,842	-52	-1,316	-2,110	-2,575	-1,525	1,247
Debt-free Net Working Capital (DFNWC)	8,984	6,603	5,479	4,678	7,356	23,036	27,979	22,935	10,370	15,854
Net Working Capital (NWC)	7,169	4,805	3,206	3,162	4,599	20,537	25,231	20,188	10,370	14,872
Net Nonoperating Expense (NNE)	674	609	1,191	1,229	128	-908	281	204	423	446
Net Nonoperating Obligations (NNO)	16,720	16,560	17,600	18,866	23,492	-1,247	-4,190	-3,152	-6,034	-4,153
Total Depreciation and Amortization (D&A)	2,767	2,693	2,103	2,050	1,480	1,404	1,429	1,286	1,158	1,098
Debt-free, Cash-free Net Working Capital to Revenue	-3.50%	-2.44%	-3.32%	-6.75%	-0.21%	-5.86%	-9.54%	-9.86%	-5.02%	3.82%
Debt-free Net Working Capital to Revenue	31.24%	24.35%	20.08%	17.13%	29.79%	102.61%	126.45%	87.85%	34.12%	48.57%
Net Working Capital to Revenue	24.93%	17.72%	11.75%	11.58%	18.63%	91.48%	114.03%	77.33%	34.12%	45.57%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.38	$4.54	$3.66	$4.96	$0.10	$4.24	$4.20	$3.54	$10.08	$12.37
Adjusted Weighted Average Basic Shares Outstanding	1.25B	1.25B	1.26B	1.26B	1.26B	1.27B	1.30B	1.31B	1.34B	1.46B
Adjusted Diluted Earnings per Share	$0.38	$4.50	$3.64	$4.93	$0.10	$4.22	$4.17	$3.51	$9.94	$11.91
Adjusted Weighted Average Diluted Shares Outstanding	1.26B	1.26B	1.26B	1.26B	1.26B	1.28B	1.31B	1.32B	1.36B	1.52B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.25B	1.25B	1.25B	1.25B	1.26B	1.26B	1.28B	1.31B	1.31B	1.37B
Normalized Net Operating Profit after Tax (NOPAT)	4,056	6,263	7,877	7,430	2,850	3,001	5,741	9,887	13,911	18,552
Normalized NOPAT Margin	14.10%	23.10%	28.87%	27.21%	11.54%	13.37%	25.94%	37.87%	45.77%	56.84%
Pre Tax Income Margin	2.40%	25.30%	21.31%	30.32%	6.76%	22.99%	35.25%	51.82%	56.26%	66.36%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.71	8.27	7.22	9.27	2.70	6.19	8.24	13.10	18.74	32.48
NOPAT to Interest Expense	1.18	6.59	6.16	7.42	0.22	4.48	5.33	4.34	14.43	26.97
EBIT Less CapEx to Interest Expense	1.17	7.65	6.44	8.69	2.04	5.36	7.38	12.57	17.96	31.40
NOPAT Less CapEx to Interest Expense	0.65	5.97	5.38	6.84	-0.44	3.65	4.47	3.81	13.65	25.88
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	816.25%	67.86%	81.23%	58.14%	3,875.28%	60.07%	54.41%	58.81%	18.20%	10.35%
Augmented Payout Ratio	1,055.83%	85.68%	111.80%	66.94%	5,653.93%	92.67%	107.53%	79.35%	99.76%	65.59%

This table displays calculated financial ratios and metrics derived from Gilead Sciences' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-0.28%	6.40%	7.01%	5.38%	5.26%	-3.72%	0.13%	5.42%	-3.61%	2.00%	-5.11%
EBITDA Growth	173.57%	19.95%	-41.76%	19.42%	-263.10%	-6.93%	1.54%	10.04%	255.32%	81.79%	-24.34%
EBIT Growth	145.12%	26.89%	-53.19%	25.98%	-376.36%	-15.64%	-4.13%	4.13%	1,680.23%	126.38%	-27.85%
NOPAT Growth	158.96%	45.92%	-52.65%	90.93%	-334.43%	-24.19%	17.97%	-28.90%	835.86%	291.43%	-27.91%
Net Income Growth	131.53%	25.83%	-42.31%	55.34%	-523.35%	-13.23%	21.61%	-8.46%	8,108.33%	334.31%	-30.94%
EPS Growth	131.14%	25.44%	-42.20%	55.42%	-517.50%	-11.63%	21.83%	-8.79%	3,900.00%	330.00%	-30.73%
Operating Cash Flow Growth	-20.82%	37.16%	145.53%	-43.33%	27.24%	-15.50%	-38.70%	29.74%	-5.22%	-19.91%	-11.99%
Free Cash Flow Firm Growth	282.68%	507.74%	45.32%	-24.51%	-217.42%	-70.04%	-48.85%	-52.86%	-53.95%	30.91%	127.06%
Invested Capital Growth	-4.81%	-8.50%	-6.63%	1.13%	-2.70%	1.29%	-0.34%	-2.77%	-0.99%	-2.81%	-7.05%
Revenue Q/Q Growth	-11.92%	0.32%	8.50%	4.01%	-6.02%	0.89%	6.85%	3.89%	-14.03%	4.93%	12.49%
EBITDA Q/Q Growth	-16.21%	65.02%	-36.84%	184.24%	-236.61%	-19.88%	29.50%	15.06%	-22.05%	-12.59%	40.35%
EBIT Q/Q Growth	-20.99%	102.35%	-47.84%	154.10%	-322.22%	-25.36%	40.40%	18.68%	-32.17%	-15.18%	52.49%
NOPAT Q/Q Growth	-11.53%	73.25%	-44.04%	168.75%	-318.94%	-43.78%	125.61%	-15.59%	-29.20%	-12.51%	35.97%
Net Income Q/Q Growth	-26.25%	42.30%	-22.37%	138.71%	-394.28%	-34.76%	109.05%	5.48%	-39.68%	-8.57%	57.36%
EPS Q/Q Growth	-27.27%	43.00%	-22.48%	138.62%	-392.98%	-34.10%	108.43%	3.75%	-37.98%	-9.15%	56.04%
Operating Cash Flow Q/Q Growth	-40.94%	-30.96%	225.21%	-40.29%	2.31%	23.59%	-24.94%	34.06%	-32.06%	-10.34%	58.88%
Free Cash Flow Firm Q/Q Growth	-32.70%	42.35%	128.74%	183.36%	-323.89%	-65.96%	18.82%	29.66%	-42.88%	-41.89%	9.52%
Invested Capital Q/Q Growth	0.39%	-1.74%	-5.60%	2.23%	-3.51%	0.27%	2.26%	-1.64%	0.44%	-1.34%	-0.24%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	76.90%	79.11%	79.14%	77.80%	76.79%	70.62%	77.80%	78.15%	77.94%	81.11%	80.19%
EBITDA Margin	39.07%	41.08%	24.97%	42.90%	-52.96%	36.44%	45.88%	37.85%	34.18%	37.69%	45.24%
Operating Margin	33.55%	32.40%	11.77%	38.02%	-64.64%	22.66%	37.20%	25.23%	26.84%	30.68%	40.29%
EBIT Margin	28.63%	31.92%	15.83%	32.92%	-63.28%	26.76%	36.18%	27.53%	24.10%	30.55%	37.79%
Profit (Net Income) Margin	19.72%	23.56%	16.61%	23.21%	-62.37%	19.92%	30.80%	15.74%	15.51%	22.10%	25.36%
Tax Burden Percent	79.75%	82.28%	131.07%	78.62%	92.96%	85.72%	93.70%	65.43%	75.77%	80.40%	73.44%
Interest Burden Percent	86.38%	89.69%	80.07%	89.69%	106.03%	86.82%	90.87%	87.40%	84.91%	89.99%	91.39%
Effective Tax Rate	20.25%	17.77%	-31.07%	21.33%	0.00%	14.28%	6.30%	34.57%	24.31%	19.60%	26.56%
Return on Invested Capital (ROIC)	20.77%	20.35%	11.52%	21.57%	-32.30%	13.49%	24.31%	11.62%	14.03%	17.09%	19.66%
ROIC Less NNEP Spread (ROIC-NNEP)	18.27%	18.95%	12.02%	19.11%	-38.24%	13.69%	22.69%	11.35%	12.40%	16.05%	18.14%
Return on Net Nonoperating Assets (RNNOA)	18.75%	15.02%	10.41%	18.39%	-38.36%	10.64%	18.47%	10.02%	11.38%	13.85%	16.69%
Return on Equity (ROE)	39.52%	35.37%	21.93%	39.96%	-70.67%	24.12%	42.78%	21.64%	25.40%	30.94%	36.36%
Cash Return on Invested Capital (CROIC)	24.33%	11.95%	8.27%	3.33%	4.48%	14.65%	17.28%	18.94%	18.19%	17.47%	18.02%
Operating Return on Assets (OROA)	14.60%	15.16%	7.66%	15.79%	-29.40%	11.58%	15.86%	12.04%	10.43%	12.71%	15.82%
Return on Assets (ROA)	10.06%	11.18%	8.04%	11.13%	-28.98%	8.62%	13.51%	6.89%	6.71%	9.20%	10.62%
Return on Common Equity (ROCE)	39.71%	35.51%	22.01%	40.11%	-70.93%	24.19%	42.88%	21.69%	25.45%	30.97%	36.38%
Return on Equity Simple (ROE_SIMPLE)	31.13%	0.00%	0.62%	5.65%	2.61%	0.00%	26.12%	25.73%	26.38%	0.00%	15.70%
Net Operating Profit after Tax (NOPAT)	1,784	2,016	1,164	2,080	-3,025	1,382	2,458	1,089	1,291	1,823	2,083
NOPAT Margin	26.76%	26.64%	15.43%	29.91%	-45.25%	19.42%	34.86%	16.51%	20.32%	24.67%	29.59%
Net Nonoperating Expense Percent (NNEP)	2.50%	1.40%	-0.51%	2.46%	5.94%	-0.21%	1.62%	0.28%	1.63%	1.04%	1.52%
Return On Investment Capital (ROIC_SIMPLE)	4.05%	4.39%	-	-	-	2.89%	-	-	-	3.93%	-
Cost of Revenue to Revenue	23.10%	20.89%	20.86%	22.20%	23.21%	29.38%	22.20%	21.85%	22.06%	18.89%	19.81%
SG&A Expenses to Revenue	18.87%	25.18%	18.99%	19.80%	20.57%	22.59%	18.65%	28.02%	20.77%	27.34%	17.23%
R&D to Revenue	24.48%	21.54%	25.18%	19.97%	84.52%	24.66%	21.95%	24.90%	30.35%	23.09%	22.68%
Operating Expenses to Revenue	43.35%	46.72%	67.37%	39.78%	141.43%	47.95%	40.60%	52.92%	51.12%	50.43%	39.90%
Earnings before Interest and Taxes (EBIT)	1,909	2,416	1,194	2,289	-4,231	1,904	2,551	1,817	1,531	2,257	2,661
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	2,605	3,109	1,884	2,983	-3,541	2,592	3,235	2,498	2,171	2,785	3,186
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.28	5.96	5.65	4.68	5.14	4.25	4.02	4.36	4.68	4.69	3.42
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	4.86	4.00	3.69	3.07	3.28	3.58	3.27	3.37	3.64	3.65	2.66
Price to Earnings (P/E)	23.39	239.83	821.89	81.10	185.91	17.12	15.26	16.82	17.62	21.69	21.66
Dividend Yield	2.77%	3.33%	3.65%	4.43%	4.17%	3.85%	4.14%	4.00%	3.73%	3.68%	5.03%
Earnings Yield	4.27%	0.42%	0.12%	1.23%	0.54%	5.84%	6.55%	5.94%	5.68%	4.61%	4.62%
Enterprise Value to Invested Capital (EV/IC)	4.33	3.66	3.35	2.73	2.91	2.89	2.72	2.85	2.98	3.02	2.30
Enterprise Value to Revenue (EV/Rev)	5.45	4.58	4.33	3.81	4.03	4.18	3.89	4.00	4.30	4.30	3.33
Enterprise Value to EBITDA (EV/EBITDA)	14.79	29.71	31.27	20.11	23.11	10.81	9.97	10.29	11.17	13.24	11.90
Enterprise Value to EBIT (EV/EBIT)	20.04	78.99	105.98	42.17	54.17	14.54	13.06	13.24	14.20	17.36	16.48
Enterprise Value to NOPAT (EV/NOPAT)	21.78	114.19	230.09	61.70	164.50	18.23	16.02	17.44	17.27	20.35	20.68
Enterprise Value to Operating Cash Flow (EV/OCF)	15.10	12.17	12.22	14.19	13.04	14.17	12.68	11.50	12.96	12.92	9.32
Enterprise Value to Free Cash Flow (EV/FCFF)	17.37	29.30	39.10	82.57	64.16	19.83	15.70	14.86	16.32	17.04	12.30
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.31	1.39	1.26	1.28	1.44	1.10	1.12	1.20	1.21	1.19	1.20
Long-Term Debt to Equity	1.16	1.29	1.17	1.18	1.23	1.02	1.04	1.01	1.10	1.08	1.09
Financial Leverage	1.03	0.79	0.87	0.96	1.00	0.78	0.81	0.88	0.92	0.86	0.92
Leverage Ratio	3.09	2.88	2.88	2.95	3.08	2.85	2.89	3.03	3.06	3.10	3.05
Compound Leverage Factor	2.67	2.59	2.30	2.65	3.26	2.47	2.62	2.65	2.60	2.79	2.79
Debt to Total Capital	56.67%	58.12%	55.83%	56.20%	59.07%	52.34%	52.90%	54.48%	54.66%	54.33%	54.50%
Short-Term Debt to Total Capital	6.37%	3.95%	4.35%	4.36%	8.60%	3.77%	3.80%	8.71%	4.94%	4.89%	4.90%
Long-Term Debt to Total Capital	50.30%	54.17%	51.48%	51.84%	50.47%	48.58%	49.10%	45.77%	49.71%	49.43%	49.60%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-0.19%	-0.18%	-0.20%	-0.20%	-0.20%	-0.18%	-0.15%	-0.14%	-0.13%	-0.07%	-0.05%
Common Equity to Total Capital	43.52%	42.06%	44.37%	44.00%	41.12%	47.83%	47.25%	45.66%	45.47%	45.74%	45.55%
Debt to EBITDA	2.36	6.02	5.93	4.43	5.27	2.38	2.34	2.37	2.42	2.85	3.32
Net Debt to EBITDA	1.61	3.77	4.65	3.91	4.28	1.58	1.59	1.62	1.73	1.99	2.41
Long-Term Debt to EBITDA	2.09	5.61	5.47	4.09	4.50	2.21	2.17	1.99	2.20	2.59	3.02
Debt to NOPAT	3.47	23.15	43.67	13.60	37.49	4.02	3.76	4.02	3.75	4.38	5.77
Net Debt to NOPAT	2.37	14.49	34.21	11.98	30.47	2.66	2.55	2.75	2.68	3.06	4.18
Long-Term Debt to NOPAT	3.08	21.58	40.26	12.54	32.03	3.73	3.49	3.38	3.41	3.99	5.25
Altman Z-Score	3.23	2.78	2.68	2.44	1.92	2.48	2.35	2.22	2.36	2.38	2.03
Noncontrolling Interest Sharing Ratio	-0.46%	-0.40%	-0.38%	-0.37%	-0.37%	-0.26%	-0.22%	-0.20%	-0.17%	-0.09%	-0.05%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.37	1.60	1.26	1.14	1.08	1.43	1.34	1.02	1.28	1.29	1.30
Quick Ratio	1.00	1.20	0.82	0.69	0.72	1.06	0.98	0.78	0.95	0.99	0.96
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	3,607	5,359	3,765	1,646	-1,974	882	2,591	2,180	1,682	2,944	5,065
Operating Cash Flow to CapEx	1,689.42%	2,023.81%	3,056.03%	1,019.23%	2,113.33%	1,008.84%	1,438.52%	1,682.01%	1,600.00%	1,418.23%	1,823.57%
Free Cash Flow to Firm to Interest Expense	13.87	21.61	15.82	6.94	-7.77	3.50	11.17	9.48	7.31	13.03	22.12
Operating Cash Flow to Interest Expense	6.76	12.00	18.11	5.59	8.74	8.61	7.56	10.17	7.58	11.36	12.50
Operating Cash Flow Less CapEx to Interest Expense	6.36	11.40	17.51	5.04	8.32	7.75	7.04	9.56	7.11	10.56	11.82
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.51	0.47	0.48	0.48	0.46	0.43	0.44	0.44	0.43	0.42	0.42
Accounts Receivable Turnover	6.35	6.33	6.04	6.25	6.22	5.75	5.99	6.56	6.80	5.89	6.08
Inventory Turnover	3.45	3.58	3.83	3.69	3.88	3.95	3.71	3.60	3.68	3.62	4.39
Fixed Asset Turnover	5.35	5.36	5.16	5.11	5.08	5.03	5.02	5.05	5.04	5.15	5.23
Accounts Payable Turnover	9.18	9.04	9.08	11.65	10.65	8.93	9.67	9.49	9.31	7.03	11.49
Days Sales Outstanding (DSO)	57.52	57.63	60.47	58.36	58.71	63.51	60.92	55.63	53.64	62.01	59.99
Days Inventory Outstanding (DIO)	105.66	102.10	95.35	98.91	94.12	92.51	98.29	101.29	99.06	100.82	83.17
Days Payable Outstanding (DPO)	39.75	40.38	40.20	31.33	34.28	40.86	37.73	38.45	39.20	51.94	31.77
Cash Conversion Cycle (CCC)	123.43	119.35	115.63	125.95	118.55	115.16	121.49	118.47	113.51	110.89	111.39
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	36,106	35,966	36,604	38,774	37,929	39,309	39,205	38,340	38,980	38,809	39,338
Invested Capital Turnover	0.78	0.76	0.75	0.72	0.71	0.69	0.70	0.70	0.69	0.69	0.66
Increase / (Decrease) in Invested Capital	-1,823	-3,343	-2,601	434	-1,051	500	-133	-1,091	-391	-1,121	-2,982
Enterprise Value (EV)	156,483	131,754	122,508	105,972	110,559	113,455	106,538	109,435	116,329	117,171	90,455
Market Capitalization	139,541	115,118	104,380	85,478	90,167	96,979	89,648	92,254	98,347	99,602	72,198
Book Value per Share	$15.39	$15.51	$14.84	$14.67	$14.07	$18.32	$17.91	$16.96	$16.84	$16.93	$16.82
Tangible Book Value per Share	($6.83)	($7.17)	($8.34)	($10.33)	($11.39)	($9.58)	($10.56)	($11.95)	($12.56)	($12.73)	($13.30)
Total Capital	44,030	45,957	41,639	41,547	42,649	47,736	47,224	46,340	46,178	46,439	46,280
Total Debt	24,952	26,711	23,249	23,350	25,194	24,987	24,982	25,246	25,239	25,230	25,223
Total Long-Term Debt	22,146	24,896	21,437	21,540	21,527	23,189	23,189	21,209	22,956	22,957	22,953
Net Debt	17,026	16,720	18,212	20,578	20,476	16,560	16,962	17,245	18,040	17,600	18,281
Capital Expenditures (CapEx)	104	147	141	130	105	215	122	139	109	181	157
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-563	-1,007	-171	574	-25	-661	-1,036	-2,307	-661	-906	-259
Debt-free Net Working Capital (DFNWC)	7,363	8,984	4,866	3,346	4,693	6,603	5,828	4,360	5,211	5,479	5,401
Net Working Capital (NWC)	4,557	7,169	3,054	1,536	1,026	4,805	4,035	323	2,928	3,206	3,131
Net Nonoperating Expense (NNE)	469	233	-89	466	1,145	-35	286	50	306	190	297
Net Nonoperating Obligations (NNO)	17,028	16,720	18,214	20,577	20,474	16,560	16,963	17,246	18,041	17,600	18,281
Total Depreciation and Amortization (D&A)	696	693	690	694	690	688	684	681	640	528	525
Debt-free, Cash-free Net Working Capital to Revenue	-1.96%	-3.50%	-0.60%	2.06%	-0.09%	-2.44%	-3.78%	-8.43%	-2.44%	-3.32%	-0.95%
Debt-free Net Working Capital to Revenue	25.62%	31.24%	17.20%	12.03%	17.10%	24.35%	21.28%	15.92%	19.27%	20.08%	19.90%
Net Working Capital to Revenue	15.86%	24.93%	10.79%	5.52%	3.74%	17.72%	14.73%	1.18%	10.83%	11.75%	11.54%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.06	$1.43	$1.00	$1.29	($3.34)	$1.14	$1.75	$0.84	$0.81	$1.30	$1.43
Adjusted Weighted Average Basic Shares Outstanding	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.26B	1.26B
Adjusted Diluted Earnings per Share	$1.04	$1.43	$1.00	$1.29	($3.34)	$1.14	$1.73	$0.83	$0.80	$1.29	$1.42
Adjusted Weighted Average Diluted Shares Outstanding	1.26B	1.26B	1.25B	1.25B	1.25B	1.26B	1.26B	1.26B	1.26B	1.26B	1.26B
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	1.24B	1.25B	1.25B	1.24B	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B
Normalized Net Operating Profit after Tax (NOPAT)	1,784	2,016	1,847	2,080	-1,324	1,425	2,458	1,089	1,291	1,823	2,083
Normalized NOPAT Margin	26.76%	26.64%	24.47%	29.91%	-19.81%	20.03%	34.86%	16.51%	20.32%	24.67%	29.59%
Pre Tax Income Margin	24.73%	28.63%	12.67%	29.52%	-67.10%	23.24%	32.87%	24.06%	20.47%	27.49%	34.54%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	7.34	9.74	5.02	9.66	-16.66	7.56	11.00	7.90	6.66	9.99	11.62
NOPAT to Interest Expense	6.86	8.13	4.89	8.78	-11.91	5.48	10.59	4.74	5.61	8.07	9.10
EBIT Less CapEx to Interest Expense	6.94	9.15	4.42	9.11	-17.07	6.70	10.47	7.30	6.18	9.19	10.93
NOPAT Less CapEx to Interest Expense	6.46	7.54	4.30	8.23	-12.32	4.63	10.07	4.13	5.14	7.26	8.41
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	66.02%	816.25%	3,410.53%	373.48%	836.24%	67.86%	64.87%	69.02%	67.39%	81.23%	111.45%
Augmented Payout Ratio	90.83%	1,055.83%	4,243.86%	465.44%	1,054.59%	85.68%	93.03%	96.99%	93.46%	111.80%	131.19%

Frequently Asked Questions About Gilead Sciences' Financials

When does Gilead Sciences's fiscal year end?

According to the most recent income statement we have on file, Gilead Sciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Gilead Sciences' net income changed over the last 9 years?

Gilead Sciences' net income appears to be on a downward trend, with a most recent value of $480 million in 2024, falling from $18.11 billion in 2015. The previous period was $5.61 billion in 2023. View Gilead Sciences' forecast to see where analysts expect Gilead Sciences to go next.

What is Gilead Sciences's operating income?

Gilead Sciences's total operating income in 2024 was $1.66 billion, based on the following breakdown:

Total Gross Profit: $22.50 billion
Total Operating Expenses: $20.84 billion

How has Gilead Sciences revenue changed over the last 9 years?

Over the last 9 years, Gilead Sciences' total revenue changed from $32.64 billion in 2015 to $28.75 billion in 2024, a change of -11.9%.

How much debt does Gilead Sciences have?

Gilead Sciences' total liabilities were at $39.75 billion at the end of 2024, a 0.9% increase from 2023, and a 21.9% increase since 2015.

How much cash does Gilead Sciences have?

In the past 9 years, Gilead Sciences' cash and equivalents has ranged from $5.34 billion in 2021 to $17.94 billion in 2018, and is currently $9.99 billion as of their latest financial filing in 2024.

How has Gilead Sciences' book value per share changed over the last 9 years?

Over the last 9 years, Gilead Sciences' book value per share changed from 12.86 in 2015 to 15.51 in 2024, a change of 20.6%.

Related Companies

This page (NASDAQ:GILD) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gilead Sciences (GILD) Financials

Frequently Asked Questions About Gilead Sciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gilead Sciences (GILD) Financials

Annual Income Statements for Gilead Sciences

Quarterly Income Statements for Gilead Sciences

Annual Cash Flow Statements for Gilead Sciences

Quarterly Cash Flow Statements for Gilead Sciences

Annual Balance Sheets for Gilead Sciences

Quarterly Balance Sheets for Gilead Sciences

Annual Metrics And Ratios for Gilead Sciences

Quarterly Metrics And Ratios for Gilead Sciences

Frequently Asked Questions About Gilead Sciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools